Yahoo Web Search

  1. Ads
    related to MERCK & CO., INC
  1. Should You Worry About Merck & Co., Inc.'s (NYSE:MRK) CEO Salary Level?

    Simply Wall St. via Yahoo FinanceNov 12 19:47 PM

    Ken Frazier became the CEO of Merck & Co., Inc. (NYSE:MRK) in 2011. This report will, first, examine the CEO compensation levels in comparison to CEO compensation at other ...

  2. Recap of the Week's Most Important Stories: EU Approval for Merck's Ebola Vaccine & AstraZeneca's New Diabetes Tablet: The European Commission' has granted conditional marketing approval ...

  3. Merck's Ebola Vaccine Gets Conditional Approval in Europe

    Zacks via Yahoo FinanceNov 12 13:05 PM

    Merck & Co., Inc. MRK announced that the European Commission has granted conditional marketing approval to its investigational vaccine for Ebola Zaire disease, V920. The ...

  4. AstraZeneca plc AZN and partner Merck MRK announced that the FDA has accepted the new drug application (NDA) seeking approval of MEK 1/2 inhibitor selumetinib for the treatment of pediatric ...

  5. 4 Big Drugmakers to Bet on After a Great Earnings Season

    Zacks via Yahoo FinanceNov 15 11:41 AM

    J&J JNJ, Bristol-Myers Merck, Novartis, Pfizer PFE, AstraZeneca, AbbVie ABBV beat estimates for both earnings and sales. Lilly and Sanofi beat the Zacks Consensus Estimate for earnings ...

  6. The JAVELIN Gastric 100 study evaluated Bavencio as a first-line maintenance therapy following induction chemotherapy in patients with unresectable, locally advanced/metastatic HER2-negative ...

  7. U.S. drugmaker Merck & Co Inc on Monday received approval from the European Commission to market (http://bit.ly/2NZ0QMB) its Ebola vaccine, less than a month after a European ...

  8. Novartis' Generics Unit to Buy Aspen's Japanese Operations

    Zacks via Yahoo FinanceNov 11 13:46 PM

    Novartis AG’s NVS generic unit Sandoz announced that it has entered an agreement to acquire the Japanese business of Aspen Global Incorporated (AGI), a wholly-owned subsidiary of Aspen Pharmacare ...

  9. Shares of Celldex Therapeutics, Inc. CLDX declined 2.5%, following its earnings release on Nov 12. The company incurred a loss of 75 cents per share in third-quarter 2019, narrower than ...

  10. Biopharmaceuticals Ltd (NASDAQ: XTLB) XOMA Corp (NASDAQ: XOMA) Zai Lab Ltd (NASDAQ: ZLAB) Zimmer Biomet Holdings Inc (NYSE: ZBH) Affimed NV (NASDAQ: AFMD) Akebia Therapeutics Inc ...

  1. Ads
    related to MERCK & CO., INC